The FDA-approved BRAF/MEK inhibitor combination of dabrafenib and trametinib has revolutionized treatment of BRAFV600E mutation positive anaplastic thyroid cancer. The gene discussed is MAP2K7; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.